|
MEK7 inhibitors for acute lymphoblastic leukemia (ALL) treatment
NU 2023-060
INVENTORS
Karl Scheidt*
Dalton Kim
Meghan Orr
SHORT DESCRIPTION
Rational design of highly potent and selective covalent MEK7 inhibitors
BACKGROUND
Acute lymphoblastic leukemia (ALL) is a deadly blood cancer, the most common hematological malignancy in patients under 14 years of age. Despite advancements in treatment, ALL relapse...
Published: 12/16/2025
|
Inventor(s):
Keywords(s): ALL - Acute Lymphoblastic Leukemia, Cancer/Oncology, Leukemia, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|